Regulatory Changes & Political Landscape - The DEA is directed to reclassify cannabis from schedule 1 to schedule 3, easing restrictions on medical research, banking, and taxes [1] - A Medicare pilot program will allow some seniors to receive up to $500 per year in hemp-derived CBD products starting in April [2] - Congress passed a ban on all hemp products starting November 2026, including CBD products under the pilot program [2] - The White House will work with Congress to update the statutory definition of final hemp-derived cannabinoid products [3] Industry Dynamics & Lobbying - There has been growing industry engagement and intensified lobbying in Washington [3] - The president shared a medical CBD commercial produced by a longtime friend [4] - Cannabis's influence in DC has seen an uptick year-over-year [6] Strategic Considerations - The executive order is testing a limited medically focused path to reform [4] - The move is appealing to states already moving ahead and keeping tighter controls in place as the 2026 election cycle approaches [4] - The president may see this as appealing to younger and senior voters as the 2026 midterm election process approaches [6]

I want to emphasize that the order I am about to sign is uh not the legalization or it doesn't legalize marijuana in any way, shape or form and in no way sanctions its use as a recreational drug. Has nothing to do with it. At the same time, the facts compel the federal government to recognize that marijuana can be uh legitimate in terms of medical applications when carefully administered.In some cases, this may include the use as a substitute for addictive and potentially lethal opioid painkillers, and they ...

Healthcare Policy - Some US Medicare patients may become eligible for CBD coverage under a Centers for Medicare & Medicaid Services initiative [1]

Industry Focus - The cannabis and mushroom industries are converging to create billion-dollar medications [1] Company Strategy - Companies in the CBD sector are developing plans to produce medications from cannabis and mushrooms [1]

Business Strategy - The company is developing plans to create billion-dollar medications from cannabis and mushrooms [1] Industry Focus - The industry is exploring the potential of cannabis and mushrooms in the pharmaceutical sector [1]

Industry Focus - The cannabis and psychedelic medicine industries are converging, with companies exploring the potential of both cannabis and mushrooms to create billion-dollar medications [1] Company Strategy - Companies are developing plans to create medications from cannabis and mushrooms [1]

Business Strategy - The company is developing plans to create billion-dollar medications from cannabis and mushrooms [1] Industry Focus - The industry is exploring the potential of cannabis and mushrooms in the pharmaceutical sector [1]

Business Strategy - The company is developing plans to create billion-dollar medications from cannabis and mushrooms [1] Industry Focus - The industry is exploring the potential of cannabis and mushrooms in the pharmaceutical sector [1]

Industry Focus - The CBD industry leaders are developing plans to create billion-dollar medications from cannabis and mushrooms [1]

Business Strategy - The company plans to develop billion-dollar medications from cannabis and mushrooms [1] Industry Focus - The industry is shifting towards the development of pharmaceuticals using cannabis and mushrooms [1]